Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Rheumatoid arthritis (RA) is a chronic inflammatory disease (a long-lasting disease causing
pain and swelling) associated with significant health problems. It is a difficult disease to
manage as the disease is often unpredictable. RA causes inflammation (swelling) of the joints
that can cause joint damage, deformity, and progressive disability and impairment. It is
estimated that 1% of the world's population suffers from this disease.
The purpose of this research study is to determine if a change in inflammation seen on the
ultrasound is a good indicator of how subjects' rheumatoid arthritis is responding to
treatment of subcutaneous abatacept at 3 weeks, 3 months, 6 months, and 12 months.